213 related articles for article (PubMed ID: 35590044)
21. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
22. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
Borek DM; Smith RC; Gruber CN; Gruber BL
Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
[TBL] [Abstract][Full Text] [Related]
23. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Yoshizawa T; Nishino T; Okubo I; Yamazaki M
Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
[TBL] [Abstract][Full Text] [Related]
25. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
Kim SJ; Cho YJ; Lee DW
Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
[TBL] [Abstract][Full Text] [Related]
26. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
27. Secondary fracture rates and risk factors 1 year after a proximal femoral fracture under FLS.
Ishizu H; Shimizu T; Yamazaki S; Ohashi Y; Sato K; Shimodan S; Iwasaki N
J Bone Miner Metab; 2023 Jul; 41(4):542-549. PubMed ID: 37037921
[TBL] [Abstract][Full Text] [Related]
28. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
[TBL] [Abstract][Full Text] [Related]
29. [Management of osteoporosis after fragility fractures].
Gosch M; Stumpf U; Kammerlander C; Böcker W; Heppner HJ; Wicklein S
Z Gerontol Geriatr; 2018 Jan; 51(1):113-125. PubMed ID: 29305651
[TBL] [Abstract][Full Text] [Related]
30. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
31. [Osteoporosis].
Gonzalez Rodriguez E; Debrach-Schneider AC; Lamy O
Rev Med Suisse; 2022 Jan; 18(764-5):56-58. PubMed ID: 35048581
[TBL] [Abstract][Full Text] [Related]
32. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
[TBL] [Abstract][Full Text] [Related]
33. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler DL; Chines A; Brandi ML; Papapoulos S; Lewiecki EM; Reginster JY; Muñoz Torres M; Wang A; Bone HG
Osteoporos Int; 2019 Jan; 30(1):71-78. PubMed ID: 30244369
[TBL] [Abstract][Full Text] [Related]
34. Effects of COVID-19 confinement on the incidence and mortality of major osteoporotic fractures: an observational study in Catalonia, Spain.
Surís X; Vela E; Clèries M; Llargués E; Camins J; Larrosa M
Arch Osteoporos; 2022 Nov; 17(1):150. PubMed ID: 36441292
[TBL] [Abstract][Full Text] [Related]
35. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
[TBL] [Abstract][Full Text] [Related]
36. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
Kamata Y; Minota S
Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
[TBL] [Abstract][Full Text] [Related]
37. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
Brown JP; Roux C; Törring O; Ho PR; Beck Jensen JE; Gilchrist N; Recknor C; Austin M; Wang A; Grauer A; Wagman RB
J Bone Miner Res; 2013 Apr; 28(4):746-52. PubMed ID: 23109251
[TBL] [Abstract][Full Text] [Related]
39. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
40. Implementation of a fracture liaison service and its effects on osteoporosis treatment adherence and secondary fracture at a tertiary care academic health system.
Scholten DJ; Bray JK; Wang KY; Lake AF; Emory CL
Arch Osteoporos; 2020 May; 15(1):80. PubMed ID: 32468516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
